Meggle Receives EXCiPACT Certification - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Meggle Receives EXCiPACT Certification


Meggle Group Wasserburg announced that it has been granted an EXCiPACT certificate. Following an inspection on the company’s manufacturing processes, quality systems, quality management, storage and distribution of pharmaceutical grade lactose, and its associated auxiliary materials used in the production process, auditors from the certifying body SGS (Société Générale de Surveillance, Hamburg, Germany) have confirmed that the Meggle Business Group Excipients & Technology complies with the quality standards of good manufacturing and good distribution practices (GMP & GDP) for its pharmaceutical excipients.

The EXCiPACT certification assures optimal product quality and security within the supply chain as a means to protect patient safety and ensure efficient cost. Since its introduction in 2013, the EXCiPACT certificate has been granted only to a dozen companies. The certificate documents the high standard to which Meggle has committed. For many years, the company has operated according to the international industrial GMP/GDP standard and ISO norms.

The quality standards as defined in EXCiPACT are specifically for manufacturing and supply of pharmaceutical excipients. To ensure compliance with the standards, and consequently for the patient safety, the certificate holders are reviewed annually and re-audited every three years.

Source: Meggle

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here